Targets › NMNAT1
1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology; next expected readout Apr 2027.
Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. (UniProt, Q9HAN9)
Open in Phaseline: the race on NMNAT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University College, London | Nicotinamide NAD+ precursor; supports mitochondrial function and neuroprotection | NMNAT1 | Phase 3 | Glaucoma, Open-Angle | Apr 2027 |
Glaucoma, Open-Angle (1)
small molecule (1)
University College, London (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.